TA
Therapeutic Areas
Tyra Biosciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Dabogratinib (ACH) | Skeletal dysplasia including Achondroplasia | Phase 2 |
| Dabogratinib (Onc) | Non-Muscle Invasive Bladder Cancer (NMIBC) | Phase 2 |
| TYRA-430 | Advanced Hepatocellular Carcinoma (HCC) & other FGF19+/FGFR4-driven solid tumors | Phase 1 |
| TYRA-200 | Intrahepatic Cholangiocarcinoma (ICC) & other FGFR2+ advanced solid tumors | Phase 1 |
Leadership Team at Tyra Biosciences
TH
Todd Harris
Chief Executive Officer
DW
Doug Warner
Chief Medical Officer
AF
Ali Fawaz
General Counsel and Secretary
JS
Jake Simson
Board Member
KC
Kelleen Chea
Office Manager
AB
Alexandra Balcer
Clinical
RC
Rafael Cassata
Regulatory affairs
ED
Elisa Daley
CLINICAL
CS
Cory Scott
Role not fully specified